Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C. Ozga M, et al. Among authors: vasu s. Am J Hematol. 2021 Jul 1;96(7):E223-E225. doi: 10.1002/ajh.26170. Epub 2021 Apr 8. Am J Hematol. 2021. PMID: 33761147 Free article. No abstract available.
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R. Ranganathan P, et al. Among authors: vasu s. Blood. 2015 Apr 23;125(17):2689-92. doi: 10.1182/blood-2014-10-607648. Epub 2015 Feb 25. Blood. 2015. PMID: 25716206 Free PMC article.
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G. Walker AR, et al. Among authors: vasu s. Leuk Lymphoma. 2016 Sep;57(9):2100-8. doi: 10.3109/10428194.2015.1135435. Epub 2016 Jan 19. Leuk Lymphoma. 2016. PMID: 26784138 Free PMC article.
MicroRNA-29b mediates altered innate immune development in acute leukemia.
Mundy-Bosse BL, Scoville SD, Chen L, McConnell K, Mao HC, Ahmed EH, Zorko N, Harvey S, Cole J, Zhang X, Costinean S, Croce CM, Larkin K, Byrd JC, Vasu S, Blum W, Yu J, Freud AG, Caligiuri MA. Mundy-Bosse BL, et al. Among authors: vasu s. J Clin Invest. 2016 Dec 1;126(12):4404-4416. doi: 10.1172/JCI85413. Epub 2016 Oct 24. J Clin Invest. 2016. PMID: 27775550 Free PMC article.
Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.
Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S. Fatehchand K, et al. Among authors: vasu s. J Biol Chem. 2016 Dec 2;291(49):25656-25666. doi: 10.1074/jbc.M116.753145. Epub 2016 Oct 25. J Biol Chem. 2016. PMID: 27780867 Free PMC article.
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.
Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N. Gopalakrishnan B, et al. Among authors: vasu s. Oncotarget. 2018 Jan 3;9(11):9706-9713. doi: 10.18632/oncotarget.23880. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515764 Free PMC article.
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W. Mims AS, et al. Among authors: vasu s. Haematologica. 2018 Jun;103(6):982-987. doi: 10.3324/haematol.2017.186890. Epub 2018 Mar 22. Haematologica. 2018. PMID: 29567781 Free PMC article. Clinical Trial.
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N. Mani R, et al. Among authors: vasu s. Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17. Haematologica. 2018. PMID: 29773600 Free PMC article.
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.
Buteyn NJ, Fatehchand K, Santhanam R, Fang H, Dettorre GM, Gautam S, Harrington BK, Henderson SE, Merchand-Reyes G, Mo X, Benson DM, Carson WE 3rd, Vasu S, Byrd JC, Butchar JP, Tridandapani S. Buteyn NJ, et al. Among authors: vasu s. Int Immunol. 2018 Jul 24;30(8):375-383. doi: 10.1093/intimm/dxy040. Int Immunol. 2018. PMID: 29868798 Free PMC article.
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.
Vasu S, Kohlschmidt J, Mrózek K, Eisfeld AK, Nicolet D, Sterling LJ, Becker H, Metzeler KH, Papaioannou D, Powell BL, Kolitz JE, Moore JO, Baer MR, Roboz GJ, Stone RM, Byrd JC, Carroll AJ, Bloomfield CD. Vasu S, et al. Blood Adv. 2018 Jul 10;2(13):1645-1650. doi: 10.1182/bloodadvances.2017015222. Blood Adv. 2018. PMID: 29991495 Free PMC article.
264 results